NasdaqGS:BMRNBiotechs
BioMarin (BMRN) Is Up 5.1% After Strong Sales, New Debt And Canadian VOXZOGO Approval
BioMarin Pharmaceutical Inc. has reported its fourth quarter and full-year 2025 results, with Q4 revenue rising to US$874.57 million and full-year revenue to US$3.22 billion, while the quarter shifted to a net loss of US$46.57 million and full-year net income eased to US$348.9 million.
The combination of higher sales but weaker quarterly profitability, alongside fresh debt financing to support the pending Amicus Therapeutics acquisition and new conditional approval for VOXZOGO in Canada,...